Treatment options of invasive fungal infections in adults
| العنوان: | Treatment options of invasive fungal infections in adults |
|---|---|
| المؤلفون: | Martin G. Täuber, Jorge Garbino, Michel P. Glauser, Jacques Bille, Oscar Marchetti, Ursula Flückiger, Alexander Imhof, Philippe Eggimann, Christian Ruef, Stefan Zimmerli, Didier Pittet, Thierry Calandra |
| المصدر: | Swiss Medical Weekly, Vol. 136, No 29-30 (2006) pp. 447-463 |
| بيانات النشر: | SMW Supporting Association, 2006. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | Azoles, medicine.medical_specialty, Antifungal Agents, Combination therapy, Polyenes/therapeutic use, Salvage therapy, Polyenes, Candidiasis/ drug therapy/epidemiology, Aspergillosis, Peptides, Cyclic, Fungal Proteins, Echinocandins, chemistry.chemical_compound, Switzerland/epidemiology, Pharmacotherapy, Aspergillosis/ drug therapy/epidemiology, Fungal Proteins/therapeutic use, Peptides, Cyclic/therapeutic use, Amphotericin B deoxycholate, medicine, Humans, Intensive care medicine, ddc:616, Voriconazole, Clinical Trials as Topic, business.industry, Candidiasis, General Medicine, bacterial infections and mycoses, medicine.disease, chemistry, Drug Therapy, Combination, Azoles/therapeutic use, Antifungal Agents/adverse effects/ therapeutic use, Caspofungin, business, Switzerland, Fluconazole, medicine.drug |
| الوصف: | A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events. |
| تدمد: | 1424-3997 1424-7860 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6aaaf07836c8237f50a7dacff12a86 https://doi.org/10.4414/smw.2006.11392 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....9d6aaaf07836c8237f50a7dacff12a86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14243997 14247860 |
|---|